A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.
about
Ebola virus vaccines: an overview of current approachesAntibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccineRhabdovirus-based vaccine platforms against henipavirusesControlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccinePreclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and FilovirusesIn silico prediction of Ebola Zaire GP(1,2) immuno-dominant epitopes for the Balb/c mouse.One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.Ebola vaccines in clinical trial: The promising candidates.Lassa-vesicular stomatitis chimeric virus safely destroys brain tumorsAn Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.Replication-incompetent rabies virus vector harboring glycoprotein gene of lymphocytic choriomeningitis virus (LCMV) protects mice from LCMV challenge.Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever
P2860
Q26999232-A2E38681-DBE9-4C82-886E-03B105742A56Q27334697-C55CD4BA-84D9-4412-914E-8A2BE2A68E27Q34992537-D8216E68-24F4-48E5-ADD4-76BFD09314A2Q35184639-FC049A3D-DAFF-42E7-AB0F-BCFA1EF48024Q36043269-BEF9BE59-22D7-4376-8BBB-B233DBE8C1C0Q36130780-2D921D78-5DF7-4980-A24E-EF1D73D09FC7Q37560824-193E16D4-A3A0-4B60-9A18-93118BB22D4AQ38808678-C4A9C730-3E2F-4D80-BE02-CC7221C1BA96Q38886667-18598A93-9457-40B5-AD9A-FDA428B8CA1EQ40095257-D72B5D6E-6FB5-4923-B3B9-3B186E41D774Q51784219-FDF7F87B-6C3E-413C-B97B-9B8CAF9761E1Q52586088-D832F821-402C-44E8-9C5E-C745AC307D8CQ57476548-E1EC2212-0BC7-4BE0-A1CB-4F0968E754DC
P2860
A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
A replication-deficient rabies ...... attenuated for neurovirulence.
@ast
A replication-deficient rabies ...... attenuated for neurovirulence.
@en
type
label
A replication-deficient rabies ...... attenuated for neurovirulence.
@ast
A replication-deficient rabies ...... attenuated for neurovirulence.
@en
prefLabel
A replication-deficient rabies ...... attenuated for neurovirulence.
@ast
A replication-deficient rabies ...... attenuated for neurovirulence.
@en
P2093
P2860
P921
P1433
P1476
A replication-deficient rabies ...... attenuated for neurovirulence.
@en
P2093
Amy B Papaneri
Christoph Wirblich
Jennifer A Cann
Joseph E Blaney
Kurt Cooper
Matthias J Schnell
P2860
P356
10.1016/J.VIROL.2012.07.020
P407
P577
2012-08-11T00:00:00Z